Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Slides:

Advertisements

Similar presentations

Statin Myopathy (AHA/ACC/NHLBI)

Advertisements

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.

The Latest Lipid Guidelines:

PCSK9 Inhibitors and Cardiovascular Outcomes Trials

Diabetic Dyslipidemia in Practice

Updates and Perspectives in Diabetic Dyslipidemia

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

PCSK9 Inhibitors Post-CVOTs

LDL Established Target for Cardiovascular Risk

Current Dyslipidemia Management Guidelines Residual Risk.

An Endocrinology Clinic in Dyslipidemia

Diabetes and Dyslipidemia

A multicenter, double-blind, randomized study to establish the clinical benefit and safety of ezetimibe/simvastatin tablet (vytorin) vs simvastatin.

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.

Clinical Trials in Residual Cardiovascular Risk: A Fresh Perspective

Cardiovascular Disease Risk Reduction Advances in Dyslipidemia

ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY.

Beyond Statin Therapy.

The Chemical Differences Between EPA and DHA.

Program Goals. What Will the Emerging Basal Insulin Products Mean for My Diabetes Practice?

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

An Update on PCSK9 Inhibitors

A Pharmacist's Guide to PCSK9 Inhibitors:

Evaluating LDL-C Recommendations

What's New in Dyslipidemia?

62-year-old Man With Unstable Angina

PCSK9 Inhibitors and Cardiovascular Outcomes

% decrease in LDL-C at 24 weeks from baseline

% decrease in LDL-C at 24 weeks from baseline

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

A Patient Journey Through Statin Intolerance

Improving Appropriate Access to PCSK9 Inhibitors

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

New LDL-C Lipid Targets

A PCP's Guide to Dyslipidemia

Radical New Concepts in Lipid Management

Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia

Clinicians' Corner in Dyslipidemia

Updates in Cardiovascular Medicine

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Residual CV Risk in Patients With Dyslipidemia and Stable CAD

Charles J. Glueck, MD, Alan Brown, MD, Anne C. Goldberg, MD, James M

Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9

Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.

Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.

PCSK9 Mutations PCSK9 Loss-of-function Mutations.

Glucose Management and Statin Therapy

LDL Cholesterol.

How to Optimize Cholesterol Management in High-Risk CV Patients

Approximate Dose Equivalency of Statin LDL-C Efficacy.

Reducing Risk for CV Outcomes

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

Lipid Updates From Spring 2019

New Lipid-Lowering Therapies

An Update on PCSK9 Inhibitors

Glucose Management and Statin Therapy

PCSK9 Inhibitors and Statin Intolerance

Updates on Dyslipidemia

Achieving Lipid Targets With PCSK9 Inhibition

Lipids, the Heart, and the Kidney

in diabetic patients with mixed dyslipidemia

PCSK9 Inhibitors and Real-World Evidence

Shared-Decision Making in Dyslipidemia

Late-Breaking Data on LDL-C Reduction

Presentation transcript:

Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Patient Presentation

On Exam

Patient Follow-Up 8 Weeks

Case Questions

Estimated Frequency of Individuals With Familial Hypercholesterolemia

Problems in Identifying FH Patients

Statin Myopathy is a Common Challenge in Lipid Management

Statins and New-Onset Type 2 Diabetes Facts and Clinical Implications

Case Questions

Therapy for Statin Intolerance

ODYSSEY FH I + II Alirocumab Significantly Reduced LDL-C From Baseline to Week 24 vs Placebo

Safety Analysis (Pooled Data From FH I and FH II)

ODYSSEY Combo Alirocumab Significantly Reduced LDL-C From Baseline to Week 25 vs Ezetimibe

ODYSSEY LONG TERM Alirocumab Maintained Consistent LDL-C Reduction Over 52 Weeks

Adverse Events of Special Interest

Post-hoc Adjudicated Cardiovascular Events*

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)